Perrigo Company plc Operating Lease Cost
Perrigo Company plc (PRGO) reported Operating Lease Cost of $13.00 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-05
- Perrigo Company plc operating lease, cost for the quarter ending 2026-06-27 was $13.00M, a 6.56% increase year-over-year.
- Perrigo Company plc operating lease, cost for the quarter ending 2026-03-28 was $10.30M, a 12.71% decline year-over-year.
- Perrigo Company plc operating lease, cost for the quarter ending 2025-12-31 was $12.00M, a 2.44% decline year-over-year.
- Perrigo Company plc operating lease, cost for the quarter ending 2025-09-27 was $12.80M, a 2.40% increase year-over-year.
- Perrigo Company plc operating lease, cost for fiscal 2025 was $48.70M, a 0.61% decline from fiscal 2024.
- Perrigo Company plc operating lease, cost for fiscal 2024 was $49.00M, a 8.65% increase from fiscal 2023.
- Perrigo Company plc operating lease, cost for fiscal 2023 was $45.10M, a 2.04% increase from fiscal 2022.
- Perrigo Company plc operating lease, cost for fiscal 2022 was $44.20M, a 14.51% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $13.00M 10-Q · filed 2026-08-05 | $23.20M 10-Q · filed 2026-08-05 | $35.30M derived: sum of 3 quarters · filed 2026-08-05 | $48.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $10.30M 10-Q · filed 2026-05-06 | $22.30M derived: sum of 2 quarters · filed 2026-05-06 | $35.10M derived: sum of 3 quarters · filed 2026-05-06 | $47.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.80M derived: sum of 2 quarters · filed 2026-02-26 | $37.00M derived: sum of 3 quarters · filed 2026-08-05 | $48.70M 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $12.80M 10-Q · filed 2025-11-05 | $25.00M derived: sum of 2 quarters · filed 2026-08-05 | $36.70M 10-Q · filed 2025-11-05 | $49.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $12.20M 10-Q · filed 2026-08-05 | $23.90M 10-Q · filed 2026-08-05 | $36.30M derived: sum of 3 quarters · filed 2026-08-05 | $48.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $11.80M 10-Q · filed 2026-05-06 | $24.10M derived: sum of 2 quarters · filed 2026-05-06 | $36.60M derived: sum of 3 quarters · filed 2026-05-06 | $49.20M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.80M derived: sum of 2 quarters · filed 2026-02-26 | $37.40M derived: sum of 3 quarters · filed 2026-02-26 | $49.00M 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $12.50M 10-Q · filed 2025-11-05 | $25.10M derived: sum of 2 quarters · filed 2025-11-05 | $36.70M 10-Q · filed 2025-11-05 | $47.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $12.60M 10-Q · filed 2025-08-06 | $24.20M 10-Q · filed 2025-08-06 | $34.90M derived: sum of 3 quarters · filed 2026-02-26 | $46.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $11.60M 10-Q · filed 2025-05-07 | $22.30M derived: sum of 2 quarters · filed 2026-02-26 | $34.10M derived: sum of 3 quarters · filed 2026-02-26 | $44.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.50M derived: sum of 2 quarters · filed 2026-02-26 | $33.10M derived: sum of 3 quarters · filed 2026-02-26 | $45.10M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $11.80M 10-Q · filed 2024-11-06 | $22.40M derived: sum of 2 quarters · filed 2024-11-06 | $34.40M 10-Q · filed 2024-11-06 | $46.90M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $10.60M 10-Q · filed 2024-08-02 | $22.60M 10-Q · filed 2024-08-02 | $35.10M derived: sum of 3 quarters · filed 2025-02-28 | $46.20M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $12.00M 10-Q · filed 2024-05-07 | $24.50M derived: sum of 2 quarters · filed 2025-02-28 | $35.60M derived: sum of 3 quarters · filed 2025-02-28 | $46.40M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $23.60M derived: sum of 2 quarters · filed 2025-02-28 | $34.40M derived: sum of 3 quarters · filed 2025-02-28 | $44.20M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $11.10M 10-Q · filed 2023-11-07 | $21.90M derived: sum of 2 quarters · filed 2023-11-07 | $31.70M 10-Q · filed 2023-11-07 | $40.30M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $10.80M 10-Q · filed 2023-08-08 | $20.60M 10-Q · filed 2023-08-08 | $29.20M derived: sum of 3 quarters · filed 2024-02-27 | $39.20M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $9.70M 10-Q · filed 2023-05-09 | $18.40M derived: sum of 2 quarters · filed 2024-02-27 | $28.40M derived: sum of 3 quarters · filed 2024-02-27 | $38.20M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $18.70M derived: sum of 2 quarters · filed 2024-02-27 | $28.50M derived: sum of 3 quarters · filed 2024-02-27 | $38.60M 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $10.00M 10-Q · filed 2022-11-08 | $19.80M derived: sum of 2 quarters · filed 2022-11-08 | $29.90M 10-Q · filed 2022-11-08 | $40.30M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | $9.80M 10-Q · filed 2022-08-09 | $19.70M 10-Q · filed 2022-08-09 | $30.30M derived: sum of 3 quarters · filed 2023-02-28 | $38.80M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $9.80M 10-Q · filed 2022-05-11 | $20.50M derived: sum of 2 quarters · filed 2023-02-28 | $29.00M derived: sum of 3 quarters · filed 2023-02-28 | $37.50M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $19.20M derived: sum of 2 quarters · filed 2023-02-28 | $27.70M derived: sum of 3 quarters · filed 2023-02-28 | $37.30M 10-K · filed 2023-02-28 | $43.40M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $8.50M 10-Q · filed 2021-11-12 | $10.60M 10-Q · filed 2020-11-05 | $17.00M derived: sum of 2 quarters · filed 2021-11-12 | $26.60M 10-Q · filed 2021-11-12 | $32.10M 10-Q · filed 2020-11-05 | $36.40M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-27 | $8.50M 10-Q · filed 2021-08-11 | $11.20M 10-Q · filed 2020-08-05 | $18.10M 10-Q · filed 2021-08-11 | $23.70M 10-Q · filed 2020-08-05 | $27.90M derived: sum of 3 quarters · filed 2021-08-11 | $38.90M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-28 | $9.60M 10-Q · filed 2021-05-12 | $11.40M 10-Q · filed 2020-05-05 | $19.40M derived: sum of 2 quarters · filed 2021-05-12 | $30.40M derived: sum of 3 quarters · filed 2021-05-12 | $41.60M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $20.80M derived: sum of 2 quarters · filed 2021-03-01 | $32.00M derived: sum of 3 quarters · filed 2021-03-01 | $43.70M 10-K · filed 2021-03-01 | ||||
| 2019-09-28 | $11.00M 10-Q · filed 2020-11-05 | $22.20M derived: sum of 2 quarters · filed 2020-11-05 | $33.90M 10-Q · filed 2020-11-05 | |||||
| 2019-06-29 | $11.20M 10-Q · filed 2020-08-05 | $23.20M 10-Q · filed 2020-08-05 | ||||||
| 2019-03-30 | $12.00M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |